Johnson & Johnson at Cowen HealthCare Conference Transcript

Mar 02, 2020 / 04:20PM GMT
Christopher DelOrefice - Johnson & Johnson - VP of IR

(technical difficulty)

measures, please refer to our SEC filings, in particular our 10-K, which discuss the risks and uncertainties around forward-looking statements, as well as our website at investor.jnj.com for reconciliations to comparable GAAP measures. Finally, any remarks regarding financial performance represent results through and including the fourth quarter of 2019. Thank you.

Questions and Answers:

Joshua Thomas Jennings - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Thank you. Well, I mean, I think everyone -- the coronavirus is in front of everyone's mind, and as it should be. We're in a little bit an unknown era here in terms of how severe things could get. We've seen what's happened in China, and there's been some movement.

But I think maybe to start off on a positive note, I think J&J should be commended for the work it's doing just in the vaccine development and also I think your looking -- or screening library of antivirals.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot